| ||Suven Life Sciences bags Pharmexcil's Gold "Patent Award" | 10/04/11 12:33|| |
| ||Suven Life Sciences Ltd has informed BSE regarding a Press Release dated October 04, 2011 titled "Suven Life Sciences bags Pharmexcil's Gold "Patent Award"|
"Suven Life Sciences Ltd (SUVEN) announces today that they bagged Pharmexcil's "Patent Award" for securing the most number of product patents during 2010/11 for their New Chemical Entities (NCE's) under Gold Category third year in a row. The Awards were presented during the "Awards Function for Exports and patents during India-LAC Pharma Business Meet" organized by Pharmexcil and by Department of Commerce, Government of India.
Suven secured 108 product patents for their NCE's during 2010-2011 from several countries including all the developed countries like USA, Europe, Japan, Australia and Canada etc. So far Suven secured a total of 445 product patents globally for their NCE's since 2002.
Suven initiated drug discovery research in 2002 and focused on central nervous system (CNS) disorders to discover and develop innovative, cost-effective medicines that address significant unmet medical needs in the treatment of cognitive impairment associated with neurodegenerative disorders such as Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson, Schizophrenia and also in the area of depression, Pain and Obesity.
"We are very pleased by the grant of these patents to Suven globally for our pipeline of molecules in CNS arena that are being developed for the treatment of various unmet medical needs which has an estimated $50 billion market potential globally" says Venkat Jasti, CEO of Suven.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. The Company has twelve (12) internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia."